Attention Deficit Hyperactivity Disorder Stimulant Medications Step Therapy Policy
Cigna national formulary step therapy policy that defines Step 1 and Step 2 long-acting stimulant products for ADHD (and related indications) and the coverage rule requiring trial of a Step 1 product prior to approval of Step 2 products; approvals are for 1 year.
Generic lisdexamfetamine capsules were added to Step 1.
Generic lisdexamfetamine chewable tablets were added to Step 2.
Criterion approving Vyvanse for binge eating disorder was removed.
Generic mixed salts of a single-entity amphetamine product extended-release capsules (generic to Mydayis) added to Step 1.
Adzenys ER removed from Step 2 Products (obsolete >3 years).
Adzenys XR-ODT authorized generic added to policy as a Step 2 Product.
Generic methylphenidate extended-release 72 mg tablets added to Step 2 Products.
Amphetamine ER ODT generic added to policy as a Step 2 Product.
Relexxii: removed reference to 'branded generic' and noted it is FDA-approved under NDA with an authorized generic; methylphenidate 72 mg tablets consolidated as authorized generic to Relexxii.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.